Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United Kingdom

Pediatric Infectious Disease Journal

Volumn 31, Issue 6, 2012, Pages 616-622

  Findlow, Helen ^a   Borrow, Ray ^a,b   Andrews, Nick ^a   Waight, Pauline ^a   Sheasby, Elizabeth ^a   Matheson, Mary ^a   England, Anna ^a   Goldblatt, David ^c   Ashton, Lindsey ^c   Findlow, Jamie ^a,b   Miller, Elizabeth ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Conjugate vaccine; Meningococcal group C; Serum bactericidal antibody

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA TOXOID CRM197; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; MENITORIX; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DIPHTHERIA; DRUG ERUPTION; DRUG FEVER; HAEMOPHILUS INFECTION; HUMAN; IMMUNOGENICITY; INFANT; INGUINAL HERNIA; MAJOR CLINICAL STUDY; MEASLES; MEASLES VACCINATION; MENINGOCOCCOSIS; MUMPS; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; PURPURIC RASH; RANDOMIZED CONTROLLED TRIAL; RUBELLA; SERUM BACTERICIDAL ANTIBODY ASSAY; SINGLE DRUG DOSE; TETANUS; TREATMENT RESPONSE; UNITED KINGDOM; VACCINATION; VIRUS INFECTION; VOMITING; WHEEZING;

ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; FEMALE; GREAT BRITAIN; HUMANS; INFANT; MALE; MENINGOCOCCAL VACCINES; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 84861526415     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31824f34e6     Document Type: Article

References (28)

1. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(suppl 1):S58-S67.
2. Department of Health. Important changes to the childhood immunization programme. Chief Medical Officer Letters. United Kingdom: Department of Health; 2006.
3. Southern J, Borrow R, Andrews N, et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with a 7-valent pneumococcal conjugate vaccine and a combination DTaP5/Hib/IPV vaccine in healthy UK infants. Clin. Vaccine Immunol. 2009;16:194-199.
4. Miller E, Andrews N, Waight P, et al. Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age. Clin Vaccine Immunol. 2011;18:367-372.
5. Department of Health. Immunisation Against Infectious Disease-The Green Book. 2006. Available at: www.dh.gov.uk/greenbook. Accessed January 7, 2011.
6. Maslanka SE, Gheesling LL, Libutti DE, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol. 1997;4:156-167.
7. Lal G, Balmer P, Joseph H, et al. Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin Diagn Lab Immunol. 2004;11:272-279.
8. Holder PK, Maslanka SE, Pais LB, et al. Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992. Clin Diagn Lab Immunol. 1995;2:132-137.
9. Phipps DC, West J, Eby R, et al. An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Methods. 1990;135:121-128.
10. Melville-Smith ME. Diphtheria and tetanus antitoxins. In: Wreghitt TG, Morgan-Capner P, eds. ELISA in the Clinical Microbiology. London: Public Health Laboratory Service; 1990:136-147.
11. Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand. 1983;11:137-144.
12. World Health Organisation Pnuemococcal Serology Reference Laboratories and Department of Pathology, University of Alabama at Birmingham. Training manual for enzyme linked immunosorbent assay for quantification of Streptococcus pneumoniae serotype specific IgG (Pn Ps ELISA). London, England and Birmingham, AL: World Health Organisation Pneumococcal Serology Reference Laboratories at the Institute of Child Health, University College London, and Department of Pathology, University of Alabama; 2007. Available at: http://www.vaccine.uab. edu/ELISA%20Protocol.pdf. Accessed April 10, 2011.
13. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780-786.
14. Käyhty H, Peltola H, Karanko V, et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147:1100.
15. Borrow R, Balmer P, and Roper MH. The Immunological Basis for Immunization Series, Module 3: Tetanus. Geneva, Switzerland: World Health Organization; 2007.
16. Galazka AM. The Immunological Basis for Immunization Series, Module 2: Diphtheria. Geneva, Switzerland: World Health Organization; 1993.
17. World Health Organization. Pneumococcal conjugate vaccines. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Tech Rep Ser. 2005;927 (Annex 2):64-98.
18. Borrow R, Goldblatt D, Finn A, et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun. 2003;71:5549-5555.
19. Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis. 2001;183:160-163.
20. Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol. 2010;17:154-159.
21. Díez-Domingo J, Cantarino MV, Torrentí JM, et al.; MenC Study Group. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J. 2010;29:148-152.
22. Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: A review. Vaccine. 2010;28:5513-5523.
23. Kitchin NR, Southern J, Morris R, et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child. 2007;92:11-16.
24. Goldblatt D, Southern J, Ashton L, et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 2006;25:312-319.
25. Givon-Lavi N, Greenberg D, Dagan R. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial. Pediatr Infect Dis J. 2010;29:756-762.
26. Gheesling LL, Carlone GM, Pais LB, et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol. 1994;32:1475-1482.
27. Richmond P, Borrow R, Findlow J, et al. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains. Infect Immun. 2001;69:2378-2382.
28. Ishola D, Borrow R, Findlow H, et al. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England, a decade after vaccine introduction. In: 11th Meeting of The European Meningococcal Disease Society, Ljubljana, Slovenia May 18-20, 2011. Wurzburg, Germany: European Meningococcal Disease Society; 2011. [Abstract P 068].